CPRX Q2 2025 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$147M+19.4% YoY

Gross Profit

$117M79.6% margin

Operating Income

$66M45.2% margin

Net Income

$52M35.6% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

+3.6%

Cash Flow

Operating Cash Flow

$71M

Free Cash Flow

$71M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$972M

Total Liabilities

$116M

Stockholders' Equity

$856M

Cash & Equivalents

$653M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$147M	$123M	+19.4%
Gross Profit	$117M	$107M	+8.7%
Operating Income	$66M	$54M	+22.2%
Net Income	$52M	$41M	+27.7%

Revenue Segments

Product Revenue Net

$147M100%

License And Other Revenue

$23,0000%